Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The addition of the mTORr inhibitor, Everolimus, to consolidation therapy in acute myeloid leukaemia: experience from the UK NCRI AML17 trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Hydrochloric acid prolongs the lifetime of central venous catheters in haematologic patients with bacteraemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Novel variants in Nordic patients referred for genetic testing of telomere-related disorders

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Systematic patient involvement for homebased outpatient administration of complex chemotherapy in acute leukemia and lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Risks of bleeding and thrombosis in intensive care unit patients with haematological malignancies

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Three-year follow-up of implementation of evidence-based transfusion practice in a tertiary hospital

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Alan K Burnett
  • Emma Das Gupta
  • Steve Knapper
  • Asim Khwaja
  • Marion Sweeney
  • Lars Kjeldsen
  • Timothy Hawkins
  • Sophie E Betteridge
  • Paul Cahalin
  • Richard E Clark
  • Robert K Hills
  • Nigel H Russell
View graph of relations

As part of the UK NCRI AML17 trial, adult acute myeloid leukaemia patients in remission could be randomised to receive the mTOR inhibitor everolimus, sequentially with post-induction chemotherapy. Three hundred and thirty-nine patients were randomised (2:1) to receive everolimus or not for a maximum of 84 days between chemotherapy courses. The primary endpoint was relapse free survival (RFS). At 5 years there was no difference in Relapse Free Survival (29% vs 40%; OR 1.19 (0.9-1.59) p=0.2), cumulative incidence of relapse (60% vs 54%: OR 1.12( 0.82-1.52): p=0.5) or overall survival (45% vs 58%: OR 1.3 (0.94-1.81): p=0.11). The independent Data Monitoring Committee advised study termination after randomisation of 339 of the intended 600 patients due to an excess mortality in the everolimus arm without any evidence of beneficial disease control. Dose delivery of everolimus was variable, but there was no evidence of clinical benefit in patients with adequate dose delivery compared with no treatment. This study suggests that the addition of mTOR inhibition to chemotherapy provides no benefit. Clinica Trial: ISRCTN55675535.

Original languageEnglish
JournalHaematologica
Volume103
Issue number10
Pages (from-to)1654-1661
ISSN0390-6078
DOIs
Publication statusPublished - 5 Jul 2018

ID: 54770285